Our findings provide evidence that AURKA inhibitor would be a therapeutic approach for the treatment of advanced HCC and TIALD may be a potential target that could enhance the activity of alisertib, that would provide a rationale for drug combination to achieve better therapeutic outcome. Here, AURKA is linked to hepatocellular carcinoma.